Article
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Cancer discovery - 1 Dec 2015
Kwak Eunice L, Ahronian Leanne G, Siravegna Giulia, Mussolin Benedetta, Borger Darrell R, Godfrey Jason T, Jessop Nicholas A, Clark Jeffrey W, Blaszkowsky Lawrence S, Ryan David P, Lennerz Jochen K, Iafrate A John, Bardelli Alberto, Hong Theodore S, Corcoran Ryan B
Abstract excerpt
UNLABELLED: MET inhibition is effective in some patients with MET-amplified esophagogastric cancer (EGC), but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired resistance in a patient after a 2-year response to a MET inhibitor. We also observed that 40% to 50% of patients with MET-amplified EGC harbor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.